What is retatrutide and how is it different from tirzepatide?
retatrutideglucagongipglp1comparison
Retatrutide is studied as a multi-agonist that targets:
- GLP-1 receptor
- GIP receptor
- Glucagon receptor
Tirzepatide is primarily studied as a dual agonist (GIP + GLP-1).
In research terms, retatrutide adds glucagon receptor activity, which may influence energy balance pathways. Clinical implications are still being studied.
For research use only. Not medical advice.
Related questions
- What is tirzepatide (GIP/GLP-1) and how is it different from semaglutide?
- What is the difference between GLP-1, GIP, and glucagon receptors?
- What does “glucagon receptor agonism” mean in retatrutide?
- Semaglutide vs tirzepatide vs retatrutide: what’s the difference (research overview)?
- What are GLP-1 receptor agonists?
- Is semaglutide a GLP-1?
Browse all FAQs about research peptides, sourcing, and Peptide Library.
View all FAQs